Tagged with Patient access

Baltics Marina Truhanova, deputy head of National Health Service Latvia, discusses the responsibility that the Latvian National Health System (NHS) has in terms of allocating their financial resources wisely, the importance of public procurement of medicines with the other two Baltic states to purchase cheaper drugs and allow for more access…

Latvia Svens Henkuzens, director of the State Agency of Medicines in Latvia discusses the key role of the organization in the country and the objectives he has set to further improve the access to innovative treatments for Latvian patients. Could you introduce the State Agency of Medicines and its mandate? “We…

Lithuania Jūratė Sabalienė, who was appointed in September 2017 as the director of the National Health Insurance Fund (NHIF) of the Republic of Lithuania, explains her commitment as well as the back-up strategy to ensure the access to medicines of all Lithuanian patients in a financially sustainable manner. Could you please…

Canada Tarik Henein, president of Generic Medical Partners, explains the company’s commitment to improving the lives of Canadians by connecting global generic development and manufacturing companies with the Canadian market. He further comments on the key points for navigating the complex Canadian pharmaceutical market and how GMP combines a unique flexibility…

Canda Richard Lajoie shares his main priorities for his tenure as new president of Valeant’s Canadian operations: portfolio rejuvenation through launches of innovative molecules addressing the unmet needs of Canadian patients, growing the company’s manufacturing capacity in the country and fostering the Valeant culture. What does Canada represent for Valeant today?…

Switzerland With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group of service providers have emerged to try and further dialogue between pharmaceutical companies, regulators, healthcare professionals and patients on the issue of expanding access to medicines. At…

Serbia Marija Krstic, general manager of GSK Serbia and Montenegro, discusses how the various positions she has undertaken during her 13-year career at GSK help inform her current role, the initiatives that GSK Serbia is involved in to increase access to innovative medicines for Serbian patients, and her push to ensure…

India A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB) in support of the Government of India’s efforts to end TB, including providing access to novel drug bedaquiline, initiating a…

Lithuania Kristina Garuoliene, vice minister at the Ministry of Health of the Republic of Lithuania, explains the cornerstones behind the new National Drug Policy approved in August 2017, the commitment of the Ministry to ensuring Lithuanian patients have access to the latest high-quality medicines regardless of their location or spending power.…

Brazil Cesar Rengifo, senior vice president and area director Emerging Markets West at GSK, the fastest growing multinational company in both Brazil and Latin America, discusses the perfect match between GSK’s product portfolio and the region’s healthcare needs as well as the opportunities it entails for the company and Latin America’s…

Poland Drago Vuina, corporate vice-president of Novo Nordisk Eastern Europe, highlights Poland as the most significant market in the region and the on-going commitment to make innovative treatment options available for patients. Furthermore, he discusses Novo Nordisk’s strong commitment to social responsibility in each country throughout the region and the need…

Switzerland Petra Doerr, head of sector communication & networking as well as deputy executive director of Swissmedic, the Swiss surveillance authority for medicines and medical devices, discusses changes to the Swiss regulatory system and harmonizing the organization with its global counterparts. Swissmedic has embarked upon a comprehensive overhaul of its regulations in response…